USE OF ALLOGENEIC EFFECTOR CELLS AND ANTI-CS1 ANTIBODIES FOR SELECTIVE KILLING OF MULTIPLE MYELOMA CELLS

1 . A method of treating multiple myeloma in a subject, the method comprising administering an effective amount of allogeneic effector cells in combination with an effective amount of HuLuc63.

2 . The method according to claim 1 , wherein said allogeneic effector cells are lymphoid or myeloid cells or a combination thereof.

3 . The method according to claim 1 , wherein said allogeneic effector cells are lymphoid cells selected from the group consisting of T cells, NK cells, B cells and/or a combination thereof.

4 . The method according to claim 3 , wherein said allogeneic effector cells are alloreactive NK cells.

5 . The method according to claim 1 , wherein said allogeneic effector cells are derived from a donor, matched or mismatched in HLA type to the host.

6 . The method according to claim 1 , further comprising administration of a conditioning regimen comprising fludarabine, dexamethasone and melphalan.

7 . The method according to claim 6 , wherein the conditioning regimen is administered prior to the administration of the allogeneic effector cells.

8 . The method according to claim 1 , wherein HuLuc63 is administered prior to the administration of the allogeneic effector cells.

9 . The method according to claim 8 , in which HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.

10 . The method according to claim 1 , wherein prior to the administration of the allogeneic effector cells and HuLuc63, the subject has undergone stem cell transplantation.

11 . The method according to claim 10 , wherein the stem cell transplantation is autologous stem cell transplantation.

12 . The method according to claim 11 , further comprising treating the subject with a maintenance regimen comprising the administration of HuLuc63.

13 . The method according to claim 12 , further comprising the administration of at one or more therapeutic agents.

14 . The method according to claim 13 , wherein at least one of the therapeutic agents is a targeted agent, a conventional chemotherapeutic agent, a hormonal therapy agent or a supportive care agent.

15 . The method according to claim 1 , wherein said subject is human.

16 . The method according to claim 1 , wherein said administration elicits a complete response.

17 . The method according to claim 1 , wherein said administration elicits a very good partial response.

18 . The method according to claim 1 , wherein said administration elicits a partial response.

19 . The method according to claim 1 , wherein said administration elicits a minimal response.

20 . The pharmaceutical composition according to claim 1 , comprising a first pharmaceutical composition comprising a therapeutically effective amount of allogeneic effector cells and a second pharmaceutical composition comprising HuLuc63.

21 . The pharmaceutical composition according to claim 20 , wherein said allogeneic effector cells are lymphoid or myeloid cells or a combination thereof.

22 . The pharmaceutical composition according to claim 21 , wherein said allogeneic effector cells are lymphoid cells selected from the group consisting of T cells, NK cells, B cells and/or a combination thereof.

23 . The pharmaceutical composition according to claim 22 , wherein said allogeneic effector cells are alloreactive NK cells.

24 . The pharmaceutical composition according to claim 20 , wherein HuLuc63 is administered at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.

25 . The pharmaceutical composition according to claim 20 , wherein administration of said pharmaceutical composition elicits a complete response.

26 . The pharmaceutical composition according to claim 20 , wherein administration of said pharmaceutical composition elicits a very good partial response.

27 . The pharmaceutical composition according to claim 20 , wherein administration of said pharmaceutical composition elicits a partial response.

28 . The pharmaceutical composition according to claim 20 , wherein administration of said pharmaceutical composition elicits a minimal response.